Abbott initiated with an Outperform at Credit Suisse. Credit Suisse analyst Matt Miksic initiated Abbott with an Outperform rating and a price target of $82 as part of his broader research note on Medical Supplies and Devices partially titled “No Disruption, No Alpha”, saying the stock offers “best exposure” to Diabetes medicine. The analyst contends that Abbott is “firing on all cylinders” with improving organic growth, sales mix, and investor returns, having produced organic revenue growth of about 8% over the last 4 quarters.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.